INTEGRAL DIAGNOSTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.47 AUD | -1.59% |
|
0.00% | +29.66% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company does not generate enough profits, which is an alarming weak point.
- The company is in debt and has limited leeway for investment
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +29.66% | 377M | B+ | ||
| -17.89% | 8.25B | B+ | ||
| +39.20% | 3.57B | C+ | ||
| -39.11% | 2.46B | B- | ||
| -8.06% | 2.46B | - | ||
| -7.35% | 2.38B | B- | ||
| -12.61% | 1.81B | C- | ||
| -19.01% | 1.55B | A- | ||
| -40.66% | 1.21B | C+ | ||
| +7.56% | 1.11B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IDX Stock
- Ratings Integral Diagnostics Limited
